Verzenio (abemaciclib) is not chemotherapy. It’s also not immunotherapy. Rather, it’s a targeted type of treatment for specific forms of breast cancer. Verzenio is known as a targeted ...

Verzenio (abemaciclib) is a brand-name oral tablet prescribed for certain forms of breast cancer. Verzenio has interactions with certain other drugs, some foods, and certain supplements.

As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...

Revenue from the breast cancer treatment Verzenio also helped in the fourth quarter, climbing 36% to $1.55 billion. Overall, Lilly’s quarterly profit swelled to $4.41 billion. Revenue advanced ...

The drug is a non-chemotherapy oral tablet. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of VERZENIO. The report also ...